Karyopharm Therapeutics Files 8-K on Financials
Ticker: KPTI · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, filing
Related Tickers: KPTI
TL;DR
Karyopharm dropped an 8-K detailing its financial condition and operations.
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 85 Wells Avenue, Newton, Massachusetts.
Why It Matters
This filing provides investors with crucial updates on Karyopharm's financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any new material adverse information.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- January 13, 2025 (date) — Date of report
- 85 Wells Avenue, Newton, Massachusetts (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing made?
The filing was made on January 13, 2025.
What is Karyopharm Therapeutics Inc.'s primary business sector?
Karyopharm Therapeutics Inc. is in the 'PHARMACEUTICAL PREPARATIONS' sector, with SIC code 2834.
Where are Karyopharm Therapeutics Inc.'s principal executive offices located?
The principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459.
What is the Commission File Number for Karyopharm Therapeutics Inc.?
The Commission File Number is 001-36167.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-01-13 08:34:48
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- kpti-20250113.htm (8-K) — 65KB
- kpti-ex99_1.htm (EX-99.1) — 90KB
- 0000950170-25-004591.txt ( ) — 289KB
- kpti-20250113.xsd (EX-101.SCH) — 30KB
- kpti-20250113_htm.xml (XML) — 5KB
02
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Karyopharm Therapeutics Inc. (the "Company") announced preliminary unaudited fourth quarter and full year 2024 total revenue and U.S. XPOVIO (selinexor) net product revenue estimates, and outlined its 2024 achievements and 2025 objectives. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued by Karyopharm Therapeutics Inc. on January 13, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: January 13, 2025 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary